Featured News
Featured Oncology News.
Phase 3 Prosper Trial Shows Xtandi® (Enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-metastatic Castration-resistant Prostate Cancer
TOKYO and NEW YORK, February 5, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today results from the Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC). The results show that the use of XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) […]
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
Analysis of 75 patients with median follow-up of more than a year demonstrated an overall remission rate of 81% Event-free survival and overall survival at six months were 73% and 90%, with median duration of remission not reached Kymriah was detected in patients up to 20 months, demonstrating long-term persistence Novartis is committed to bringing […]
New Study Examines the Longest-Running CAR T Cell Trial and Finds Acute Lymphoblastic Leukemia Patients May Do Better When Treated Early
New York, NY, Wednesday, January 31, 2018 – Researchers at Memorial Sloan Kettering (MSK) report today in the New England Journal of Medicine that adult patients with acute lymphoblastic leukemia (ALL) who received chimeric antigen receptor (CAR) T cell therapy responded better if they had a small amount of disease at the time of the […]
Proof of Principle: Tri-Institutional Therapeutics Discovery Institute Drug Candidates “Graduate” to Next Phase of Development
Monday, January 22, 2018 – When the Tri-Institutional Therapeutics Discovery Institute launched just over four years ago, nothing like it existed in academia. The nonprofit academic corporation – a joint venture between Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine, with Takeda Pharmaceutical Company Ltd. as their partner – was tasked […]
Pro Football Hall of Famer and Cancer Survivor Jim Kelly Joins Merck to Challenge America to Raise Funds for the Cancer Community
30-Day Your Cancer Game Plan Challenge Helps Those Impacted by Cancer and the Patient Organizations That Support Them KENILWORTH, N.J. January 31, 2018 –(BUSINESS WIRE)–With an estimated 1.6 million Americans diagnosed in 2017 alone, cancer not only impacts those diagnosed but their friends and family as well. In recognition of World Cancer Day on Sunday, […]
Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma
Phase 1/2 Study Planned for 2018 FOSTER CITY, Calif. & SANTA MONICA, Calif.–(BUSINESS WIRE)–Jan. 18, 2018– Kite, a Gilead Company (Nasdaq: GILD), announced it has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the investigational combination of Yescarta™ (axicabtagene ciloleucel) and Pfizer’s utomilumab, a fully humanized 4-1BB agonist monoclonal antibody, in patients with […]
Lynparza approved by US FDA in germline BRCA-mutated metastatic breast cancer
Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer Lynparza reduced the risk of disease progression or death by 42% compared to standard of care chemotherapy 12 January 2018 – AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that […]
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma Paris and Tarrytown, N.Y. – January 8, 2018 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will accelerate and expand investment for the clinical development of the PD-1 (programmed cell death protein 1) antibody cemiplimab in oncology and dupilumab in Type 2 allergic diseases. […]